Represents the aggregate development costs.

No definition available.

Name:	nerv_AggregateDevelopmentCosts
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of fees related to termination of the agreement.

+ References

No definition available.

+ Details

Name:	nerv_FeesForTerminationOfAgreement
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of cash outflow for license fees paid during the period.

+ References

No definition available.

+ Details

Name:	nerv_PaymentsOfLicenseFees
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the percentage of development costs related to joint development of any products for which the entity is responsible.

+ References

No definition available.

+ Details

Name:	nerv_PercentageOfDevelopmentCostsRelatedToJointDevelopmentOfProducts
Namespace Prefix:	nerv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the period within which the entity terminates the agreement.

+ References

No definition available.

+ Details

Name:	nerv_PeriodWithinWhichAgreementIsTerminated
Namespace Prefix:	nerv_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name:	us-gaap_CommonStockSharesSubscribedButUnissued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

CO-DEVELOPMENT AND LICENSE AGREEMENT (Details) (USD $)	6 Months Ended	0 Months Ended			1 Months Ended	0 Months Ended
CO-DEVELOPMENT AND LICENSE AGREEMENT (Details) (USD $)	Jun. 30, 2013	Feb. 12, 2014 Co-development and license agreement MIN-202 Period one Maximum	Feb. 12, 2014 Co-development and license agreement MIN-202 Period two Maximum	Feb. 12, 2014 Co-development licensor Co-development and license agreement MIN-202	Jul. 31, 2014 Co-development licensor Co-development and license agreement MIN-202 Subsequent event	Jul. 07, 2014 Co-development licensor Common stock purchase agreement Subsequent event	Feb. 12, 2014 Co-development licensor Common stock purchase agreement Maximum
Co-development and license agreement
Payments of License Fees					$ 22,000,000
Percentage of development costs related to joint development of products				40.00%
Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies		5,000,000	24,000,000
Period within which agreement is terminated related to Phase Ib clinical trials milestone				45 days
Termination fees related to Phase Ib clinical trial milestone				3,000,000
Common stock agreed to be issued (in shares)							26,000,000
Common stock issued (in shares)						3,284,353
Net proceeds from issuance of common stock	$ 1,850,000					$ 19,700,000